PRED MILD (prednisolone acetate) by AbbVie is clinical pharmacology prednisolone acetate is a glucocorticoid that, on the basis of weight, has 3 to 5 times the anti-inflammatory potency of hydrocortisone. First approved in 1972.
Drug data last refreshed 2d ago
PRED MILD is a prednisolone acetate ophthalmic suspension indicated for ocular inflammation, allergic conjunctivitis, anterior uveitis, and retinal conditions. It is a glucocorticoid with 3-5 times the anti-inflammatory potency of hydrocortisone that inhibits edema, fibrin deposition, capillary dilation, and phagocytic migration. This topical drop formulation addresses a broad spectrum of anterior and posterior segment inflammatory eye diseases.
Modest Part D volume (3,337 claims, $799K spend) indicates a mature, stable product approaching loss of exclusivity with limited commercial growth potential.
CLINICAL PHARMACOLOGY Prednisolone acetate is a glucocorticoid that, on the basis of weight, has 3 to 5 times the anti-inflammatory potency of hydrocortisone. Glucocorticoids inhibit the edema, fibrin deposition, capillary dilation, and phagocytic migration of the acute inflammatory response, as…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Comparison of 0.5% Loteprednol Etabonate Versus 1% Prednisolone Acetate Following Cataract Surgery
Study of Difluprednate vs. Prednisolone Acetate on Visual Acuity, and Corneal Edema Following Cataract Surgery.
A Bioequivalence Study of Tobramycin and Prednisolone Acetate Compared to PredForte
Comparison of Hylastan to Methylprednisolone Acetate in Patients With Symptomatic Osteoarthritis of the Knee
A Study to Compare Ocular Safety and Tolerability of Eye Drops Containing Prednisolone Acetate in Patients With Intraocular Inflammation After Cataract Surgery
Worked on PRED MILD at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moPRED MILD shows minimal linked job activity, reflecting its mature, stable commercial profile with limited growth initiatives. Career opportunities are primarily in sustaining operations (regulatory, supply chain, field) rather than strategic expansion roles.